

Agilex Sales in a New Direction: Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs

Kurt Sales as Chief Scientific Officer will lead future growth and solidify Agilex Biolabs' position as a global leader in bioanalytical support services.

THEBARTON, SOUTH AUSTRALIA,
AUSTRALIA, May 27, 2022

/EINPresswire.com/ -- Agilex Biolabs has appointed Dr. Kurt Sales (B.Sc (MED)Hons. MSc. PhD. PGCM) as its new Chief Scientific Officer. Dr. Sales has extensive experience in applied and academic research, preclinical

drug development, clinical study support, and business development and management. In 2021, Dr. Sales led the company in establishing a state-of-the-art, \$1.5m specialized bioanalytical laboratory for vaccines and immunotherapy.



Dr Kurt Sales - CSO

"Kurt is a perfect fit in this role, his experience and innovative spirit have been critical to some of our recent service expansions. His transition into this new leadership role feels like a very natural evolution for Agilex," commented Jason Valentine, CEO. "He keeps a finger on the pulse of what's new and promising in therapeutics and has a knack for anticipating what kind of tools and support customers need for success. That instinct paired with his scientific excellence positions Kurt to lead our team in building robust new service areas and staying at the forefront of innovation."

Dr. Sales started his career in the medical field, gravitating toward pharmacology and neuroscience after losing two close family members to cancer and neurocognitive disease. "From that experience I developed a deep passion and was really driven towards a cure, or at least to provide information that would help the medical field understand why these things happen as we get older and how we can improve treatment for patients," said Dr. Sales. He went on to publish 45 peer-reviewed scientific papers and develop a patented mechanism for targeting cancer cells.

After 15 years in academia, Dr. Sales entered the world of drug development to apply his knowledge to advancing promising therapies into the clinic. He led the immunology group at Charles River Laboratories in Edinburgh, UK and gained business development experience at CPR Pharma Services in Adelaide, South Australia.

Dr. Sales joined Agilex Biolabs in 2017. “My role within the CRO sphere has always been a dual one,” said Dr. Sales. “My research background equips me to manage operations, but at the same time my experience enables me to engage in scientific and forward-looking conversations with biopharma leaders to determine how we can develop superior, dependable support for our customers and shape the drug development landscape in a way that improves health outcomes.”

In his five years at Agilex Biolabs, Dr. Sales has championed scientific engagement efforts and expanded support offerings to include immunobiology, cell and gene therapy, and vaccines. His goal as CSO will be to maximize efforts that cement Agilex Biolabs as a global leader in supporting clinical and nonclinical drug development. In the immediate future, Dr. Sales’ primary focus will be on the newest facility at the Agilex Biolabs campus focused on large molecule bioanalysis. His goal will be positioning the new team as a major asset to biopharma companies around the world who are shepherding large molecule drug candidates through the drug development pipeline.

“As Chief Scientific Officer, I have the opportunity to leverage my experience to accelerate promising therapies through the clinic so they can get to patients who need them – it’s amazing to work with a group of passionate scientists who all have the same goal.”

Kurt Sales has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, and a Bachelors of Science in Medicine with Honours in Pharmacology, and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organisation and Management and a Post Graduate Certificate in Management.

###

About Agilex Biolabs

Agilex Biolabs is Australia’s leading provider of bioanalytical services and toxicology studies supporting preclinical and clinical drug development. With over 25 years of specialized experience and a rapidly growing suite of full-service offerings, Agilex equips biopharma companies from United States, Asia-Pacific, and European regions with reliable, defensible data as they advance novel therapeutics through the development pipeline. By combining specialized expertise, technological innovation, and a 25-year track record, the Agilex team has successfully supported hundreds of preclinical and clinical trials from around the world. Agilex Biolabs is headquartered in Adelaide, South Australia, with additional laboratory sites in Queensland. For more information, visit <https://www.agilexbiolabs.com/>

Janki Patel

Agilex Biolabs

janki.patel@agilexbiolabs.com

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/573898394>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.